TOP STORIES

• BUSINESS Diabetes Treatments: Their Development and Market
  February 20, 2012

• BUSINESS 6 SGLT-2 Inhibitors in Final Development Stage, Applications Expected in 2013
  February 17, 2012

• BUSINESS Sanofi-aventis Nichi-Iko Obtains Approval for Allegra Generic Ahead of Competitors
  February 16, 2012

• REGULATORY Over 30 Companies Target Nu-lotan Generic Listing in June, 60% Pricing Rule to Apply
  February 15, 2012

• BUSINESS Dispensing Pharmacies Set to Reopen in Disaster-Hit Areas
  February 14, 2012

• REGULATORY Healthcare Providers, Bill Payers in Face-Off Over Additional Premiums for Generic Name Prescriptions
  February 13, 2012

• BUSINESS Nichi-Iko to Shift Back Priority to Its Own Generics from Transferred Long-Listed Products
  February 13, 2012

• ORGANIZATION NPhA Compiles Draft Proposal for Mutual Understanding to Improve Distribution
  February 10, 2012

• BUSINESS Teijin Aims for ¥400 Billion in Sales in Healthcare by FY2020
  February 9, 2012

• BUSINESS Novartis President Mitani Says Diovan Patent Expiry an “Urgent Issue”
  February 8, 2012

• BUSINESS JCR to Push Joint Development with GSK, Including New Biopharmaceuticals
  February 7, 2012

• BUSINESS US, European Pharmaceutical Companies Supported by Steady Japan Business Growth
  February 6, 2012

• BUSINESS Number of MRs Breaks 60,000; Could Become Major Topic in Light of Strained Healthcare Finances
  February 6, 2012

• BUSINESS Eisai Says Impact from Generic Versions of Aricept Insignificant
  February 3, 2012

• BUSINESS Chugai Pharmaceutical to Promote Executive VP Kosaka as President and COO
  February 2, 2012

• BUSINESS Kyowa Kirin Development Chief Hanai Set to Become Company President
  February 1, 2012

• REGULATORY CSIMC General Assembly Establishes Premium for Prescriptions by Generic Name
  January 31, 2012

• REGULATORY JPO Decides Lipitor Crystal Form “Valid”, Sandoz Calls for Appeal
  January 30, 2012

• ORGANIZATION JPWA Board of Directors Approve By-Category Talks to Be Common Understanding
  January 27, 2012

• REGULATORY Rule Review in Similar Drug Re-Pricing Yields 50 Exemptions Based on Competitiveness
  January 26, 2012

ページ

• « 先頭
• ‹ Prev
• …
• 238
• 239
• 240
• 241
• 242
• 243
• 244
• 245
• 246
• …
• Next ›
• 最終 »